# A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

> **NCT01996332** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 1805 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT01996332
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 1805 (ACTUAL)
- **Last updated:** 2014-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01996332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01996332, "A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01996332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*